Volume 28, Issue 2 - Generics and biosimilars

Regulatory pathways for development and submission activities

Author: Yousuf Mohiuddin Mohammed

Abstract

Download the full article

References

1. European Union. Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the community code relating to medicinal products for human use. OJ L 311, 28.11.2001; 2001.
2. European Parliament. Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004. Official Journal of the European Union 2016; L 378/1.
3. European Medicines Agency. European Medicines Agency pre-authorisation procedural advice for users of the centralised procedure [cited 2019 Mar 20]. Available from: https://www.ema.europa. eu/en/ documents/regulatory-proceduralguideline/ european-medicines-agencypre- authorisation-procedural-advice-userscentralised- procedure_en-0.pdf.
4. van Oers C. EU regulatory procedures – strategic choices. Doc Player (Slides) [cited 2019 Mar 20]. Available from: Available from: https://docplayer.net/26236342-Euregulatory- procedures-strategicchoices. html.
5. Prilla S. Legal basis & types of approvals. EMA SME info day on 26-Oct-2018, Regulatory Affairs Office, Scientific and Regulatory Management Department. EMA; 2018.
6. European Commission. Volume 2A Procedures for marketing authorisation, Chapter 1, marketing authorisation. 2016[cited 2019 Mar 20]. Available from: Available from: https://ec.europa.eu/health/sites/health/ files/files/eudralex/vol-2/vol2a_chap1 _rev6_201612.pdf.
7. MHRA. UKPAR: Prostap®3 DCS 11.25 mg powder and solvent for prolo.PL 16189/0013. 2015 [cited 2019 Mar 20]. Available from: Available from: http://www.mhra.gov.uk/ home/groups/par/documents/websiteres ources/con120444.pdf.
8. European Medicines Agency. Scientific guidelines [cited 2019 Mar 20] Available from: Available from: https://www.ema.europa.eu/ en/human-regulatory/researchdevelopment/ scientific-guidelines
9. European Medicines Agency. Clinical efficacy and safety: clinical pharmacology and pharmacokinetics [cited 2019 Mar 20]. Available from: Available from: https://www.ema.europa. eu/en/human-regulatory/researchdevelopment/ scientificguidelines/ clinical-efficacy-safety-clinicalpharmacology- pharmacokinetics.
10. European Medicines Agency. Productspecific bioequivalence guidance [cited 2019 Mar 20]. Available from: Available from: https://www.ema.europa.eu/en/humanregulatory/ research-development/ scientific-guidelines/clinicalpharmacology- pharmacokinetics/productspecific- bioequivalence-guidance.
11. European Medicines Agency Committee for Medicinal Products on Human Use. Prasugrel film-coated tablets 5 and 10 mg product-specific bioequivalence guidance, effective 1 November 2016. 2016. EMA/CHMP/158772/2016[cited 2019 Mar 20]. Available from: Available from: https://www.ema.europa.eu/en/ documents/scientific-guideline/prasugrelfilm- coated-tablets-5-10-mg-productspecific- bioequivalence-guidance_en.pdf.
12. European Medicines Agency Committee for Medicinal Products on Human Use. Overview of comments received on ‘Prasugrel hydrochloride film-coated tablets 5 mg and 10 mg product-specific bioequivalence guidance’ (EMA/CHMP/158772/2016/Rev.1). 2017. [cited 2019 Mar 20]. Available from: Available from: https://www.ema.europa.eu/en/ documents/comments/overviewcomments- received-prasugrelhydrochloride- film-coated-tablets-5-mg- 10-mg-product-specific_en.pdf.
13. European Medicines Agency Committee for Medicinal Products on Human Use. Prasugrel hydrochloride film-coated tablets 5 mg and 10 mg product-specific bioequivalence guidance, effective 1 December 2018. 2018. EMA/CHMP/158772/2016/Rev.1 [cited 2019 Mar 20]. Available from: Available from: https://www.ema.europa.eu/en/ documents/scientific-guideline/prasugrelhydrochloride- film-coated-tablets-5-mg- 10-mg-product-specific-bioequivalenceguidance_ en.pdf.
14. Generics and Biosimilars Initiative. Biosimilars approved in Europe. 2018 [cited 2019 Mar 20]. Available from: Available from: http://www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-Europe.
15. European Medicines Agency Committee for Medicinal Products on Human Use. Pelmeg Public assessment report, Procedure No. EMEA/H/C/004700/0000. EMA/703393/2018; 2018.
16. European Medicines Agency. Biosimilar medicines: Overview [cited 2019 Mar 20]. Available from: Available from: https://www.ema.europa. eu/en/human-regulatory/overview/ biosimilar-medicines-overview
17. Bundesinstitut für Arzneimittel und Medizinprodukte. Enoxaparin public assessment report. DE/H/5020/001- 007/DC.2018 [cited 2019 Mar 20]. Available from: Available from: https://mri.ctsmrp. eu/Human/Downloads/DE_H_ 5020_001_PAR.pdf.
18. Bundesinstitut für Arzneimittel und Medizinprodukte Teriparatide – Public assessment report. DE/H/4291/01/DC. 2018 [cited 2019 Mar 20]. Available from: Available from: https://mri.cts-mrp.eu/Human/ Downloads/DE_H_4292_001_PAR.pdf.
19. European Medicines Agency Committeefor Medicinal Products on Human Use. Terrosa Assessment reportprocedure no. EMEA/H/C/003916/0000. EMA/84371/2017. 2016 [cited 2019 Mar 20]. Available from: Available from: https://www.ema.europa.eu/en/ documents/assessment-report/ terrosa-epar-public-assessmentreportven. pdf.
20. European Medicines Agency Committee for Medicinal Products on Human Use. Guideline on clinical development of fixed combination medicinal product, Rev 2 EMA/CHMP/158268/2017; 2017.
21. European Medicines Agency Committee for Medicinal Products on Human Use. Guideline on the pharmacokinetic and clinical evaluation of modified release dosage forms (EMA/CPMP/EWP/280/96 Corr1). EMA/CHMP/EWP/280/96.; 2014 [cited 2019 Mar 20]. Available from: Available from: https://www.ema.europa.eu/en/ documents/scientific-guideline/guidelineclinical- development-fixed-combinationmedicinal- products-revision-2_en.pdf.
22. Bundesinstitut für Arzneimittel und Medizinprodukte. Amlodipine/ Atorvastatin Assessment report, DE/H/5154/01-04/DC; 2019 [cited 2019 Mar 20]. Available from: Available from: https://mri.ctsmrp. eu/Human/Downloads/DE_H_5154 _001_PAR.pdf.
23. European Medicines Agency Committee for Medicinal Products on Human Use. Glyxambi – Public assessment report, Procedure No. EMEA/H/C/003833/0000. EMA/749639/2016; 2016.
24. Bundesinstitut für Arzneimittel und Medizinprodukte. Olmesartan – HCT Assessment report. DE/H/4604/001- 004/DC.; 2016 [cited 2019 Mar 20]. Available from: Available from: https://mri.cts-mrp.eu/ Human/Downloads/DE_H_4604_004_ PAR.pdf.
25. US Food & Drug Administration. United States Code, Title 21. FD&C Act, [cited 2019 Mar 20]. Available from: Available from: https://www.fda.gov/regulatory information/lawsenforcedbyfda/federal fooddrugandcosmeticactfdcact/default.htm.
26. US Food and Drug Administration. NDA Classification codes; 2015 [cited 2019 Mar 20]. Available from: Available from: https://www.fda.gov/ downloads/AboutFDA/CentersOffices/ OfficeofMedicalProductsandTobacco/ CDER/ManualofPoliciesProcedures/ UCM470773.pdf.
27. US Food and Drug Administration. Guidance – Generics [cited 2019 Mar 20]. Available from: Available from: https://www.fda.gov/ drugs/guidancecomplianceregulatoryinfor mation/guidances/ ucm064995.htm.
28. US Food and Drug Administration. Dissolution methods, [cited 2019 Mar 20]. Available from: Available from: https://www.accessdata.fda.gov/scripts/ cder/dissolution/dsp_getallData.cfm
29. US Food and Drug Administration. Product-specific guidances for generic drug development [cited 2019 Mar 20] Available from: Available from: https://www.fda.gov/drugs/ guidancecomplianceregulatoryinformation /guidances/ucm075207.htm.
30. US Food and Drug Administration. Guidance for industry 1999: Applications covered by Section 505(b)(2) [cited 2019 Mar 20]. Available from: Available from: https://www.fda.gov/downloads/Drugs/ Guidances/ucm079345.pdf.
31. US Food and Drug Administration. Guidance for Industry 2017: Determining whether to submit an ANDA or a 505(b)(2) Application, [cited 2019 Mar 20]. Available from: Available from: https://www.fda.gov/ downloads/Drugs/GuidanceCompliance RegulatoryInformation/Guidances/ UCM579751.pdf.
32. US Food and Drug Administration. Frequently asked questions about therapeutic biological products; 2015 [cited 2019 Mar 20]. Available from: Available from: https://www.fda.gov/drugs/ developmentapprovalprocess/ howdrugsaredevelopedandapproved/ approvalapplications/therapeutic biologicapplications/ucm113522.htm.
33. US Food and Drug Administration. Biosimilars; 2018 [cited 2019 Mar 20]. Available from: Available from: https://www.fda.gov/ drugs/ developmentapprovalprocess/ howdrugsaredevelopedandapproved/ approvalapplications/therapeutic biologicapplications/biosimilars/ default.htm.
34. US Food and Drug Administration. NDA 21-426 for omnitrope; 2001 [cited 2019 Mar 20]. Available from: Available from: https://www.accessdata.fda.gov/ drugsatfda_docs/appletter/2006/021426s 000LTR.pdf.
35. Biosimilars Review and Report. Biosimilar approval status [cited 2019 Mar 20]. Available from: Available from: https://biosimilarsrr.com/ us-biosimilar-filings/.
36. Hung A, Vu Q, Mostovoy L. A systematic review of US biosimilar approvals: What evidence does the FDA require and how are manufacturers responding? J Manag Care Spec Pharm. 2017;23(12):1234-44.
37. US Food and Drug Administration. Statement from FDA commissioner Scott Gottlieb, M.D., on new actions advancing the agency’s biosimilars policy framework; 2018 [cited 2019 Apr 02]. Available from: Available from: https://www.fda.gov/NewsEvents/Newsr oom/PressAnnouncements/ucm628121. htm
38. US Food and Drug Administration. Types of applications; 2014 [cited 2019 Mar 25]. Available from: . Available from: https://www.fda.gov/ Drugs/DevelopmentApprovalProcess/ HowDrugsareDevelopedandApproved/ ApprovalApplications/default.htm.
39. Bhaswat S. Clinical development of biosimilars. Slideshare (Slide) [cited 2019 Apr 09]. Available from: Available from: https://de.slideshare.net/ bhaswatchakraborty/clinical-developmentof- biosimilars.
40. Malvern. Drug development accelerating time to market (Brochure) [cited 2019 Apr 09]. Available from: Available from: https://www.alfatest.it/keyportal/uploads /malvern-pharma-brochure_001.pdf.
41. Milto JD. FDA incentives. US-FDA 2014 (Slide) [cited 2019 Mar 25]. Available from: Available from: https://www.ema.europa.eu/ en/documents/presentation/presentationfda- incentives-john-d-milto_en.pdf.
42. Dirnagl AJ, Cocoli MA. Global generic pharmaceutical industry review, CRD Healthcare; 2016 [cited 2019 Apr 09]. Available from: Available from: https://www.krungsri.com/bank/ getmedia/a5599675-701b-49d8-a857- 33d247c773a0/BTMU-Research-201602- 29.aspx.
43. MassBio. Demystifying generic drug development: Obstacles & solutions; 2016 [cited 2019 Apr 09]. Available from: Available from: http://files.massbio.org/file/DD- 03252016.pdf.
44. Jankowsky R. Cinfa Biotech: Overcoming the challenges of biosimilar development as a mid-sized player. (Slide); 2016 [cited 2019 Apr 09]. Available from: Available from: https://slideplayer.com/slide/12564141/.